Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Maline_Michael_1000x714_ENV

Michael D. Maline

Partner

New York +1 212 841 1018

  • About
  • Representative Matters
  • Credentials
  • About

    Michael Maline is a leading securities and capital markets lawyer with significant experience representing global investment banks, issuers, and investors in public and private capital markets transactions. He regularly advises clients in initial public offerings, follow-on offerings, private placements of equity and debt securities, and other transactions ‒ focusing on cross-border offerings for foreign issuers selling securities into the United States as well as offerings for U.S. companies. Michael also advises clients on corporate and securities compliance and reporting matters.

    Michael brings a deep understanding of alternative financing techniques such as confidentially marketed public offerings (CMPOs), bought deals, registered direct offerings (RDs), private investments in public equity (PIPEs), and at-the-market offerings (ATMs) to his work with clients across a wide range of industries, from growth sectors such as life sciences and technology to media, sports and consumer products.

    Areas of Expertise

  • Practices and Industries
  • Representative Matters

    Initial Public Offering Representations

    • BTIG, LLC as lead underwriter in Gain Therapeutics, Inc.’s initial public offering.
    • Citigroup Global Markets as lead underwriter in Arsanis, Inc.’s initial public offering.
    • Cowen and Company as lead underwriter in MaxCyte, Inc.’s initial public offering.
    • JMP Securities as lead underwriter in Summit Therapeutics PLC’s (UK) initial public offering.
    • J.P. Morgan and Stifel as joint global coordinators and joint book-running managers in RenalytixAI plc’s (UK) initial public offering.
    • J.P. Morgan as lead underwriter in G1 Therapeutics, Inc.’s initial public offering.
    • J.P. Morgan as lead underwriter in Intrexon Corporation’s initial public offering.
    • Piper Jaffray & Co. as lead underwriter in Innocoll AG’s (Germany) initial public offering.
    • Piper Jaffray & Co. as lead underwriter in Itamar Medical Ltd.’s (Israel) initial U.S. public offering.
    • Piper Jaffray & Co. as lead underwriter in MDxHealth SA’s (Belgium) initial public offering.
    • SVB Leerink as lead underwriter in Centogene N.V.’s (The Netherlands) initial public offering.

    Follow-On Offering Representations

    • Cowen and Company as lead underwriter in Protara Inc.’s $150 million concurrent public offering of common and preferred stock.
    • Credit Suisse as lead underwriter in Centogene N.V.’s (The Netherlands) $50 million primary and secondary public offering.
    • Deutsche Bank Securities Inc. as lead underwriter in Orient-Express Hotels Ltd.’s three public offerings raising aggregate gross proceeds of $400 million.
    • Goldman Sachs & Co. LLC as lead underwriter in Fulcrum Therapeutics, Inc.’s $125 million follow-on offering.
    • Goldman Sachs & Co. LLC as lead underwriter in Fulcrum Therapeutics, Inc.’s $86 million follow-on offering.
    • Goldman Sachs & Co. and J.P. Morgan in follow-on offerings for Sarepta Therapeutics, Inc. raising aggregate gross proceeds of over $1.0 billion.
    • Goldman Sachs & Co. LLC as lead underwriter in Krystal Biotech, Inc.’s $100 million follow-on offering.
    • Jefferies as lead underwriter in Solutia Inc.’s $160 million follow-on offering.
    • JMP Securities as lead underwriter in Flamel Technologies, S.A.’s (France) $105 million follow-on offering.
    • J.P. Morgan as lead underwriter in NPS Pharmaceuticals, Inc.’s $87 million follow-on offering.
    • Morgan Stanley as lead underwriter in a $162 million public offering by existing shareholders of Horizon Pharma, Inc.
    • Piper Sandler & Co. as lead underwriter in Black Diamond Therapeutics, Inc.’s $75 million follow-on offering
    • Piper Jaffray & Co. as sole underwriter in Global Eagle Entertainment Inc.’s $190 million follow-on offering.
    • William Blair & Company as lead underwriter in Viking Therapeutics, Inc.’s $275 million follow-on offering.
    • William Blair & Company as lead underwriter in Viking Therapeutics, Inc.’s $175 million follow-on offering.

    Alternative Transaction Representations

    • BTIG as sole underwriter in a $100 million “bought deal” for Ginkgo Bioworks Holdings Inc.
    • BTIG as sole underwriter in two “bought deals” for Cerus Corporation.
    • Cowen and Company as lead placement agent in Invitae Corporation’s $275 million PIPE to finance its acquisition of Archer DX.
    • Cowen and Company as lead placement agent in Horizon Pharma Inc.’s $150 million 5% convertible note offering.
    • Deutsche Bank Securities as placement agent in a $600 million registered direct offering for The St. Joe Company.
    • Deutsche Bank Securities Inc. as lead placement agent in Smith & Wesson Holding Corporation’s two registered direct offerings.
    • Jefferies as lead placement agent in TFF Pharmaceuticals, Inc.’s $26 million PIPE.
    • Piper Sandler & Co. as sole placement agent in Humacyte, Inc.’s $175 million PIPE to finance its business combination with Alpha Healthcare Acquisition Corp.
    • Truist Securities as sole placement agent in Verastem, Inc.’s $60 million PIPE.

    Areas of Expertise

  • Credentials
    Education
    • Tulane University School of Law, J.D., 1994
        • magna cum laude
        • Order of the Coif
    • Johns Hopkins University, B.A., 1988
    Bar Admissions
    • New York
    • Massachusetts
    Accolades
    • New York Super Lawyers, Securities & Corporate Finance (2012-2020)

    Areas of Expertise

News and Insights

Events